A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

January 10, 2025

Study Completion Date

June 10, 2025

Conditions
NAFLDObesityType 2 DiabetesDyslipidemiasMetabolic Syndrome
Interventions
DRUG

Saroglitazar

4 Mg Oral Tablet

Trial Locations (19)

Unknown

RECRUITING

Gastroplus Digestive Disease Centre, Ahmedabad

RECRUITING

Mission GastroHospital, Ahmedabad

RECRUITING

Artemis Hospital, Gūrgaon

RECRUITING

Medanta- TheMedicity, Gūrgaon

RECRUITING

Malla ReddyNarayanaMultispecialtyHospital, Hyderabad

RECRUITING

Osmania GeneralHospital, Hyderabad

RECRUITING

Yashoda Hospitals, Hyderabad

RECRUITING

CARE CHL -Hospitals (Unit ofConvenient HospitalLtd., Indore

RECRUITING

S R Kalla MemorialGastro and GenralHospital, Jaipur

RECRUITING

AIIMS, Khorda

RECRUITING

Medanta Hospital, Lucknow

RECRUITING

Dayanand MedicalCollege & Hospital, Ludhiāna

RECRUITING

Neurociti Hospital, Ludhiāna

RECRUITING

TNMC & BYL NairCh. Hospital, Mumbai

RECRUITING

Shree Siddhivinayak Maternity & Nursing Home, Nashik

RECRUITING

Sir GangaramHospital, New Delhi

RECRUITING

Alchemist Hospital, Panchkula

RECRUITING

Fortis Hospital, Rupnagar

RECRUITING

BAPS Pramukh Swami Hospital, Sūrat

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY

NCT05872269 - A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities | Biotech Hunter | Biotech Hunter